Foundation Medicine Announcrs Discovery of Novel, Clinically Actionable Gene Fusion NTRK1 in Lung Cancer
Medicine (NASDAQ: FMI) today announced that the discovery of a
novel and potentially clinically actionable oncogenic gene fusion in
lung cancer, NTRK1, using FoundationOne™, was published in the
current online edition of Nature Medicine1.
Lung cancer remains the leading cause of cancer-related death in men and
women in the United States2; however, the use of targeted
therapies in lung cancer has led to significant clinical benefit for
patients with EGFR mutations and ALK fusions. Therefore,
the identification of new, drug-sensitive oncogenes in this disease is
of great clinical interest and has the potential to expand treatment
options for patients.
“Our understanding of cancer complexity is increasing, and